InvestorsHub Logo

mick

04/04/20 8:16 PM

#508696 RE: mick #508695

30 mins., Accula SARS-CoV-2 test Mesa Biotech Inc. Developing a molecular point-of-care test to diagnose COVID-19; development and clinical testing are being done in collaboration with Wang Guangfa, head of the Department of Pulmonary Medicine at Peking University First Hospital in Beijing; will receive technical assistance and more than $561,000 in immediate funding to pursue FDA clearance or approval of a point-of-care test for the SARS-CoV-2 virus; the grant, awarded under the Biomedical Advanced Research and Development Authority (BARDA); visually read test using polymerase chain reaction technology for results in approximately 30 minutes received emergency use authorization by the FDA to detect SARS-CoV-2 via throat and nasal swab samples

https://www.bioworld.com/COVID19diagnostics